Tandem Diabetes Care (TNDM) Capital Expenditures Growth (3y) (2016 - 2026)
Tandem Diabetes Care (TNDM) Capital Expenditures Growth (3y) (2016 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 198.70 Bn | 193.10 Bn | 7.27 Bn | -0.66% |
| 2 | Stryker | 125.85 Bn | 122.37 Bn | 4.50 Bn | 9.94% |
| 3 | Medtronic | 118.44 Bn | 109.22 Bn | 6.41 Bn | 8.89% |
| 4 | Boston Scientific | 72.64 Bn | 72.10 Bn | 3.85 Bn | 10.89% |
| 5 | Edwards Lifesciences | 51.94 Bn | 47.69 Bn | 1.35 Bn | 11.78% |
| 6 | Dexcom | 34.48 Bn | 32.53 Bn | 830.00 Mn | 12.81% |
| 7 | GE HealthCare Technologies | 33.60 Bn | 31.49 Bn | 2.18 Bn | 12.62% |
| 8 | Koninklijke Philips | 26.30 Bn | 22.98 Bn | 4.55 Bn | 19.51% |
| 9 | Steris | 23.00 Bn | 22.52 Bn | 684.20 Mn | 9.52% |
| 10 | Tandem Diabetes Care | 1.56 Bn | 1.10 Bn | 144.78 Mn | -29.25% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -29.25% |
| Mar 31, 2026 | -10.79% |
| Dec 31, 2025 | 200.24% |
| Sep 30, 2025 | 251.21% |
| Jun 30, 2025 | -68.82% |
| Mar 31, 2025 | 72.07% |
| Dec 31, 2024 | -177.55% |
| Sep 30, 2024 | 916.33% |
| Jun 30, 2024 | 278.65% |
| Mar 31, 2024 | 473.94% |
| Dec 31, 2023 | -24.97% |
| Sep 30, 2023 | -38.75% |
| Jun 30, 2023 | 48.49% |
| Mar 31, 2023 | 9.27% |
| Dec 31, 2022 | -66.80% |
| Sep 30, 2022 | -26.49% |
| Jun 30, 2022 | 33.16% |
| Mar 31, 2022 | 64.81% |
| Dec 31, 2021 | 34.34% |
| Sep 30, 2021 | -26.10% |